Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H9J2
UPID:
RM44_HUMAN
Alternative names:
39S ribosomal protein L44, mitochondrial
Alternative UPACC:
Q9H9J2; Q53S16; Q6IA62; Q9H821
Background:
Large ribosomal subunit protein mL44, also known as 39S ribosomal protein L44, mitochondrial, plays a crucial role in the 39S subunit of mitochondrial ribosome. It is instrumental in the assembly and stability of nascent mitochondrial polypeptides exiting the ribosome, highlighting its importance in mitochondrial protein synthesis.
Therapeutic significance:
The protein is linked to Combined oxidative phosphorylation deficiency 16, a mitochondrial disorder characterized by symptoms such as hypertrophic cardiomyopathy and liver steatosis. This association underscores the potential of targeting mL44 in therapeutic strategies aimed at mitigating the effects of this disease.